Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01359644 · ClinicalTrials.gov registry record · Phase 2
Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 350
- Enrollment target
NCT01359644 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 350 participants.
The verdict
NCT01359644, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 350 participants
- Enrollment target
Study Summary
The purpose of the study is to determine whether therapy with the combination of PSI-7977 and daclatasvir (BMS-790052) with or without ribavirin is effective in treating hepatitis C virus (HCV) infection when given for 12 or 24 weeks as measured by sustained virologic response with undetectable HCV RNA 12 weeks post treatment
Interventions
- DRUG Ribavirin
- DRUG Daclatasvir
- DRUG PSI-7977
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2011-06 |
| Est. Completion | 2013-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01359644
The ClinicalTrials.gov registry entry for NCT01359644 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ribavirin is the first listed.
NCT01359644 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01359644 about?
NCT01359644 is a clinical study titled "Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care". The purpose of the study is to determine whether therapy with the combination of PSI-7977 and daclatasvir (BMS-790052) with or without ribavirin is effective in treating hepatitis C virus (HCV) infection when given for 12 or 24 weeks as measured by sustained virologic response with undetectable HCV ...
What is the current status of trial NCT01359644?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 350 participants. The study started on 2011-06. Estimated completion is 2013-10.
What interventions are being tested in trial NCT01359644?
The interventions under investigation include: Ribavirin (DRUG), Daclatasvir (DRUG), PSI-7977 (DRUG).
Who is sponsoring clinical trial NCT01359644?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.